The EF CLIF–Boehringer Ingelheim Research Program is designed to accelerate progress for patients with decompensated cirrhosis. By linking EF CLIF’s clinical and biobank resources with Boehringer Ingelheim’s drug discovery and data science capabilities, the collaboration aims to identify disease-driving mechanisms and biomarkers that can guide patient stratification and enable the development of new, disease-modifying treatment approaches.

“EF CLIF was created to bridge clinical insight and translational science in chronic liver failure, in particular for acute-on-chronic liver failure (ACLF)”, said EF CLIF Director Richard Moreau. “Partnering with Boehringer Ingelheim allows us to fully leverage our data, our biobank, and our global network to accelerate the translation of discoveries into validated therapeutic and biomarker opportunities, always with patients at the center.”

“Decompensated cirrhosis is one of the most devastating and poorly understood stages of liver disease”, said Boehringer Ingelheim’s Global Head of Cardiovascular-Renal-Metabolic Diseases Research, Søren Tullin. “Through this partnership with EF CLIF, we aim to better understand patient trajectories and translate those insights into innovative therapeutic concepts and biomarkers that could ultimately change the outlook for patients. EF CLIF is a particularly attractive partner given their multiple, high-impact contributions to date.”

EF CLIF has built a unique end-to-end translational platform that brings together large-scale clinical data from thousands of patients worldwide from landmark prospective clinical trials, rich clinical metadata, advanced multi-omics capabilities, and access to well-characterized patient samples. Boehringer Ingelheim has a long-standing commitment to liver disease research and works with leading academic and clinical partners to accelerate the discovery of new therapeutic concepts and biomarkers across advanced chronic liver disease and cirrhosis. The company will contribute with its deep computational and data science expertise to help translate EF CLIF’s multi-omics datasets and clinical insights into novel disease understanding and the identification of new therapeutic options. Together, the aim is to move rapidly from data-driven signals to biological understanding and laboratory validation, shortening the path from discovery to clinically relevant insights.

The collaboration will focus on patient segmentation, mapping disease pathways, and biomarker discovery using transcriptomic and proteomic technologies. Looking ahead, the partners believe that this collaboration can chart new territory towards innovative treatment options as well as biomarkers for patients with decompensated cirrhosis. It exemplifies an innovative model of co-creation between a biopharmaceutical leader and a non-profit research foundation to address one of the world’s most challenging health needs.